Cargando…

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis

BACKGROUND: The combination of cyclin-dependent kinases 4/6 inhibitors (CDK4/6is) and endocrine therapy (ET) is standard of care for patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (BC). However, studies evaluating adjuvant CDK4/6is provided contradictory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agostinetto, E., Vian, L., Caparica, R., Bruzzone, M., Ceppi, M., Lambertini, M., Pondé, N., de Azambuja, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010395/ https://www.ncbi.nlm.nih.gov/pubmed/33743330 http://dx.doi.org/10.1016/j.esmoop.2021.100091

Ejemplares similares

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis
por: Nader-Marta, G., et al.
Publicado: (2022)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
por: Matikas, A., et al.
Publicado: (2020)

Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
por: Caparica, R., et al.
Publicado: (2021)

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
por: Molinelli, C., et al.
Publicado: (2023)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Poggio, Francesca, et al.
Publicado: (2018)

Twenty years of anti-HER2 therapy-associated cardiotoxicity
por: Pondé, Noam F, et al.
Publicado: (2016)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019)

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
por: Matutino, Adriana, et al.
Publicado: (2018)

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
por: Lambertini, Matteo, et al.
Publicado: (2020)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis
por: Caparica, Rafael, et al.
Publicado: (2021)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
por: Ma, Jun, et al.
Publicado: (2023)

Oncofertility counselling in premenopausal women with HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
por: Tagliamento, Marco, et al.
Publicado: (2021)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
por: Gao, Hong-Fei, et al.
Publicado: (2021)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

The Exciting New Field of HER2-Low Breast Cancer Treatment
por: Eiger, Daniel, et al.
Publicado: (2021)

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
por: Yam, Clinton, et al.
Publicado: (2018)

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
por: Botticelli, Andrea, et al.
Publicado: (2022)

Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
por: Jeong, Hyehyun, et al.
Publicado: (2022)

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
por: Roberto, Michela, et al.
Publicado: (2021)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
por: Futamura, Manabu, et al.
Publicado: (2023)

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
por: Lambertini, Matteo, et al.
Publicado: (2022)

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
por: Ji, Danyang, et al.
Publicado: (2023)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fog5vini8crjelaa72dum4d0vj